High-throughput autoantibody analysis in malignant pleural effusion and tuberculosis pleural effusion

Background: Malignant pleural effusion (MPE) and tuberculosis pleural effusion (TPE) are 2 kinds of common pleural diseases. Finding efficient and accurate biomarkers to distinguish the 2 is of benefit to basic and clinical research. In the present study, we carried out the first high-throughput autoantibody chip to screen the beneficial biomarker with samples of MPE and TPE and the corresponding serum. Methods: We collected pleural effusion and serum of patients with MPE (n=10) and TPE (n=10) who had been in Beijing Chao-Yang hospital from June 2013 to August 2014. Using RayBio Human Protein Array-G2 to measure the concentration of 487 defined autoantibodies. Results: Fold changes of Bcl-2-like protein 11 (BIM) autoantibody in MPE-serum/TPE-serum and MPE/TPE groups were 10 (P=.019) and 6 (P=.001); for decorin autoantibody, MPE-serum/TPE-serum ratio was 0.6 (P=.029), and MPE/TPE ratio was 0.3 (P<.001). Conclusion: BIM autoantibody is a promising MPE biomarker by high-throughput autoantibody analysis in MPE and TPE.